BRAIN CYCLOSPORIN A LEVELS ARE DETERMINED BY ONTOGENIC REGULATION OF MDR1A EXPRESSION

Cyclosporin A (CyA) toxicity is a common occurrence in pediatric organ transplant patients. We hypothesized that reduced mdr1a expression in newborn and developing mice would affect CyA accumulation within organs and/or toxicity. For functional studies, CyA was administered (5 mg kg –1 i.p.) to 1-...

Full description

Saved in:
Bibliographic Details
Published inDrug metabolism and disposition Vol. 34; no. 2; pp. 288 - 295
Main Authors GORALSKI, Kerry B, ACOTT, Philip D, FRASER, Albert D, WORTH, David, SINAL, Christopher J
Format Journal Article
LanguageEnglish
Published Bethesda, MD American Society for Pharmacology and Experimental Therapeutics 01.02.2006
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Cyclosporin A (CyA) toxicity is a common occurrence in pediatric organ transplant patients. We hypothesized that reduced mdr1a expression in newborn and developing mice would affect CyA accumulation within organs and/or toxicity. For functional studies, CyA was administered (5 mg kg –1 i.p.) to 1-, 12-, and 19-day, and adult male and female mdr1a + / + and mdr1a –/– mice. Peak blood CyA was lower in 1-, 12-, and 19-day-old (1000 ng ml –1 ) versus adult (1500 ng ml –1 ) mice but was similar in mdr1a + / + and mdr1a –/– mice. Kidney mdr1a expression (measured by quantitative polymerase chain reaction) increased 2.5-fold in 19-day-old male and female mice and increased another 4-fold in adult females compared with adult males. Liver mdr1a expression increased 6-fold by day 12 compared with neonatal mice. Thereafter, maintenance of hepatic mdr1a expression in females and a reduction to neonatal levels in males was observed. Kidney/blood (8- to 9-fold) and liver/blood (12- to 15-fold) CyA levels were highest on days 12 and 19 and were not dependent on maturational changes in mdr1a mRNA levels. Adults had higher brain expression of mdr1a mRNA (3-fold), a corresponding 5-fold increase in immunodetectable P-glycoprotein, and 80% lower brain accumulation of CyA compared with 1-day-old mice. Conversely, in mdr1a -null mice, brain/blood CyA was similar in newborn and adult mice. A similar pattern was observed for the brain accumulation of the mdr1a substrate 3 H-digoxin. We conclude that the risk for central nervous system drug toxicity could be higher in neonates or young children as a consequence of underdeveloped P-glycoprotein.
AbstractList Cyclosporin A (CyA) toxicity is a common occurrence in pediatric organ transplant patients. We hypothesized that reduced mdr1a expression in newborn and developing mice would affect CyA accumulation within organs and/or toxicity. For functional studies, CyA was administered (5 mg kg –1 i.p.) to 1-, 12-, and 19-day, and adult male and female mdr1a + / + and mdr1a –/– mice. Peak blood CyA was lower in 1-, 12-, and 19-day-old (1000 ng ml –1 ) versus adult (1500 ng ml –1 ) mice but was similar in mdr1a + / + and mdr1a –/– mice. Kidney mdr1a expression (measured by quantitative polymerase chain reaction) increased 2.5-fold in 19-day-old male and female mice and increased another 4-fold in adult females compared with adult males. Liver mdr1a expression increased 6-fold by day 12 compared with neonatal mice. Thereafter, maintenance of hepatic mdr1a expression in females and a reduction to neonatal levels in males was observed. Kidney/blood (8- to 9-fold) and liver/blood (12- to 15-fold) CyA levels were highest on days 12 and 19 and were not dependent on maturational changes in mdr1a mRNA levels. Adults had higher brain expression of mdr1a mRNA (3-fold), a corresponding 5-fold increase in immunodetectable P-glycoprotein, and 80% lower brain accumulation of CyA compared with 1-day-old mice. Conversely, in mdr1a -null mice, brain/blood CyA was similar in newborn and adult mice. A similar pattern was observed for the brain accumulation of the mdr1a substrate 3 H-digoxin. We conclude that the risk for central nervous system drug toxicity could be higher in neonates or young children as a consequence of underdeveloped P-glycoprotein.
Cyclosporin A (CyA) toxicity is a common occurrence in pediatric organ transplant patients. We hypothesized that reduced mdr1a expression in newborn and developing mice would affect CyA accumulation within organs and/or toxicity. For functional studies, CyA was administered (5 mg kg super(-1) i.p.) to 1-, 12-, and 19-day, and adult male and female mdr1a super(+) super(/) super(+) and mdr1a super(-/-) mice. Peak blood CyA was lower in 1-, 12-, and 19-day-old (1000 ng ml super(-1)) versus adult (1500 ng ml super(-1)) mice but was similar in mdr1a super(+) super(/) super(+) and mdr1a super(-/-) mice. Kidney mdr1a expression (measured by quantitative polymerase chain reaction) increased 2.5-fold in 19-day-old male and female mice and increased another 4-fold in adult females compared with adult males. Liver mdr1a expression increased 6-fold by day 12 compared with neonatal mice. Thereafter, maintenance of hepatic mdr1a expression in females and a reduction to neonatal levels in males was observed. Kidney/blood (8- to 9-fold) and liver/blood (12- to 15-fold) CyA levels were highest on days 12 and 19 and were not dependent on maturational changes in mdr1a mRNA levels. Adults had higher brain expression of mdr1a mRNA (3-fold), a corresponding 5-fold increase in immunodetectable P-glycoprotein, and 80% lower brain accumulation of CyA compared with 1-day-old mice. Conversely, in mdr1a-null mice, brain/blood CyA was similar in newborn and adult mice. A similar pattern was observed for the brain accumulation of the mdr1a substrate super(3)H-digoxin. We conclude that the risk for central nervous system drug toxicity could be higher in neonates or young children as a consequence of underdeveloped P-glycoprotein.
Cyclosporin A (CyA) toxicity is a common occurrence in pediatric organ transplant patients. We hypothesized that reduced mdr1a expression in newborn and developing mice would affect CyA accumulation within organs and/or toxicity. For functional studies, CyA was administered (5 mg kg(-1) i.p.) to 1-, 12-, and 19-day, and adult male and female mdr1a+/+ and mdr1a-/- mice. Peak blood CyA was lower in 1-, 12-, and 19-day-old (1000 ng ml(-1)) versus adult (1500 ng ml(-1)) mice but was similar in mdr1a+/+ and mdr1a-/- mice. Kidney mdr1a expression (measured by quantitative polymerase chain reaction) increased 2.5-fold in 19-day-old male and female mice and increased another 4-fold in adult females compared with adult males. Liver mdr1a expression increased 6-fold by day 12 compared with neonatal mice. Thereafter, maintenance of hepatic mdr1a expression in females and a reduction to neonatal levels in males was observed. Kidney/blood (8- to 9-fold) and liver/blood (12- to 15-fold) CyA levels were highest on days 12 and 19 and were not dependent on maturational changes in mdr1a mRNA levels. Adults had higher brain expression of mdr1a mRNA (3-fold), a corresponding 5-fold increase in immunodetectable P-glycoprotein, and 80% lower brain accumulation of CyA compared with 1-day-old mice. Conversely, in mdr1a-null mice, brain/blood CyA was similar in newborn and adult mice. A similar pattern was observed for the brain accumulation of the mdr1a substrate 3H-digoxin. We conclude that the risk for central nervous system drug toxicity could be higher in neonates or young children as a consequence of underdeveloped P-glycoprotein.
Author David Worth
Albert D. Fraser
Christopher J. Sinal
Kerry B. Goralski
Philip D. Acott
Author_xml – sequence: 1
  givenname: Kerry B
  surname: GORALSKI
  fullname: GORALSKI, Kerry B
  organization: Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada
– sequence: 2
  givenname: Philip D
  surname: ACOTT
  fullname: ACOTT, Philip D
  organization: Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada
– sequence: 3
  givenname: Albert D
  surname: FRASER
  fullname: FRASER, Albert D
  organization: Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada
– sequence: 4
  givenname: David
  surname: WORTH
  fullname: WORTH, David
  organization: Toxicology Laboratory, Capital Health, Queen Elizabeth II Sciences Centre, Halifax, Nova Scotia, Canada
– sequence: 5
  givenname: Christopher J
  surname: SINAL
  fullname: SINAL, Christopher J
  organization: Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17496409$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/16303871$$D View this record in MEDLINE/PubMed
BookMark eNpFkM9P2zAYhq2JCQrjuuPky3ZLsWM7P44hNV2kkKC0neBk2Y5NMyVNiakm_vsZtVJP76tPz_cenmtwsRt3BoDvGM0xDuldO7RzjNgcoZiG8RcwwyzEAULp8wWY-UBBylh0Ba6d-4sQppSkl-AKRwSRJMYzsLlvsqKC-Ute1qunuvE9gyX_w8sVzBoOF3zNm8ei4gt4_wLral0veVXksOHLTZmti7qC9QN8XDQ4g_z5qeGrlb99A1-t7J25PeUN2Dzwdf47KOtlkWdloElC3wOstLKxbSNpW6KSkFATKUYUTRS1ShrGFGYYRdrqVmncRrG2jLYmZIlMI0PIDfh13N1P49vBuHcxdE6bvpc7Mx6cwKm3QhLmwfkR1NPo3GSs2E_dIKcPgZH4FCm8SN-ZOIr0Dz9Oywc1mPaMn8x54OcJkE7L3k5ypzt35mKaRhSlZ27bvW7_dZMR-62cBqnHfnz9EISKUIRJQv4D5xKDXw
CODEN DMDSAI
CitedBy_id crossref_primary_10_1016_j_biomaterials_2009_09_048
crossref_primary_10_1021_tx300395w
crossref_primary_10_1111_j_1440_1681_2010_05362_x
crossref_primary_10_1016_j_neuro_2010_10_006
crossref_primary_10_1038_pr_2015_119
crossref_primary_10_1124_dmd_107_018556
crossref_primary_10_2967_jnumed_110_083949
crossref_primary_10_1016_j_taap_2013_12_019
crossref_primary_10_1021_jf104786t
crossref_primary_10_1210_en_2009_0794
crossref_primary_10_1016_j_brainres_2010_08_016
crossref_primary_10_1016_j_ejps_2009_10_005
crossref_primary_10_1016_j_ejps_2019_105119
crossref_primary_10_1096_fj_202101552RR
crossref_primary_10_1016_j_foodchem_2012_01_069
crossref_primary_10_1124_pr_109_002014
crossref_primary_10_3390_ijms18122544
crossref_primary_10_1002_jlcr_1604
crossref_primary_10_1016_j_brainres_2006_11_037
crossref_primary_10_1080_03602530802605040
crossref_primary_10_1002_bdd_752
crossref_primary_10_3389_fphar_2021_630904
crossref_primary_10_3389_fnins_2015_00021
crossref_primary_10_1097_FTD_0000000000000087
crossref_primary_10_15406_aowmc_2018_08_00234
crossref_primary_10_1074_jbc_M700793200
crossref_primary_10_1124_dmd_123_001517
crossref_primary_10_3389_fncel_2022_949412
crossref_primary_10_1124_dmd_107_018747
crossref_primary_10_1208_s12248_019_0340_z
crossref_primary_10_1039_C6FO00938G
Cites_doi 10.1016/S0021-9258(19)52451-6
10.1016/0092-8674(94)90212-7
10.1002/aja.1002020209
10.1681/ASN.2004100882
10.1073/pnas.86.2.695
10.1016/j.transproceed.2004.01.051
10.1023/A:1010984110732
10.1146/annurev.bi.62.070193.002125
10.1016/j.transproceed.2003.12.053
10.1046/j.1440-169X.2003.00699.x
10.1172/JCI118214
10.1042/bj3260539
10.1023/B:PHAM.0000033017.52484.81
10.2310/6650.2001.33969
10.2165/00003088-200342020-00001
10.1097/00007890-200208270-00024
10.1007/s004670050607
10.1159/000047185
10.1016/j.transproceed.2004.01.013
10.1177/153537020523000206
10.1128/MCB.9.3.1346
10.1038/sj.jp.7210633
10.1046/j.1472-8206.2003.00140.x
10.1006/meth.2001.1262
10.1124/dmd.30.3.283
10.1002/(SICI)1097-4695(19990605)39:3<383::AID-NEU5>3.0.CO;2-4
10.1111/j.1476-5381.1996.tb15775.x
10.1124/dmd.105.003640
10.1007/s004670100602
10.1007/s004180050159
10.1007/s00467-003-1347-2
10.1016/S0009-9120(01)00235-1
10.1210/en.142.6.2686
10.1073/pnas.94.8.4028
10.1038/sj.bjp.0705227
ContentType Journal Article
Copyright 2006 INIST-CNRS
Copyright_xml – notice: 2006 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TK
DOI 10.1124/dmd.105.007427
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Neurosciences Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Neurosciences Abstracts
DatabaseTitleList
Neurosciences Abstracts
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1521-009X
EndPage 295
ExternalDocumentID 10_1124_dmd_105_007427
16303871
17496409
34_2_288
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
08R
0R
2WC
4.4
53G
5GY
5RE
5VS
AAPBV
AAWZA
ABFLS
ABSGY
ACGFS
ACIWK
ACPRK
ADACO
AENEX
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FH7
FRP
GJ
GX1
H13
HZ
IH2
INIJC
KM
KQ8
LSO
O0-
O9-
OK1
P2P
R0Z
RHF
RHI
RPT
SJN
W2D
WH7
WOQ
---
.GJ
0R~
18M
ABSQV
ACGFO
ADBBV
AFOSN
AI.
BAWUL
BTFSW
F9R
HZ~
IQODW
TR2
VH1
W8F
YCJ
YHG
ZGI
ZXP
~KM
ABJNI
AERNN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TK
ID FETCH-LOGICAL-c384t-1bcbf7fd6afd3b8234e6b53b48b4fbae55b15106cfcdbc1d67cf54de258a96e33
ISSN 0090-9556
IngestDate Fri Oct 25 07:09:14 EDT 2024
Fri Aug 23 02:56:16 EDT 2024
Sat Nov 02 12:31:03 EDT 2024
Sun Oct 22 16:03:39 EDT 2023
Tue Jan 05 21:17:02 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Ciclosporin
Immunosuppressive agent
Central nervous system
Encephalon
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c384t-1bcbf7fd6afd3b8234e6b53b48b4fbae55b15106cfcdbc1d67cf54de258a96e33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 16303871
PQID 19742385
PQPubID 23462
PageCount 8
ParticipantIDs proquest_miscellaneous_19742385
crossref_primary_10_1124_dmd_105_007427
pubmed_primary_16303871
pascalfrancis_primary_17496409
highwire_pharmacology_34_2_288
ProviderPackageCode RHF
RHI
PublicationCentury 2000
PublicationDate 2006-02-01
PublicationDateYYYYMMDD 2006-02-01
PublicationDate_xml – month: 02
  year: 2006
  text: 2006-02-01
  day: 01
PublicationDecade 2000
PublicationPlace Bethesda, MD
PublicationPlace_xml – name: Bethesda, MD
– name: United States
PublicationTitle Drug metabolism and disposition
PublicationTitleAlternate Drug Metab Dispos
PublicationYear 2006
Publisher American Society for Pharmacology and Experimental Therapeutics
Publisher_xml – name: American Society for Pharmacology and Experimental Therapeutics
References 2019091113251873000_34.2.288.22
(2019091113251873000_34.2.288.14) 1996; 270
(2019091113251873000_34.2.288.15) 2001; 61
(2019091113251873000_34.2.288.13) 1998; 2
(2019091113251873000_34.2.288.21) 2001; 49
(2019091113251873000_34.2.288.7) 2001; 18
2019091113251873000_34.2.288.8
2019091113251873000_34.2.288.9
(2019091113251873000_34.2.288.31) 1995; 275
2019091113251873000_34.2.288.19
2019091113251873000_34.2.288.1
2019091113251873000_34.2.288.17
(2019091113251873000_34.2.288.20) 1951; 193
2019091113251873000_34.2.288.39
2019091113251873000_34.2.288.16
(2019091113251873000_34.2.288.26) 1995; 202
2019091113251873000_34.2.288.38
2019091113251873000_34.2.288.3
2019091113251873000_34.2.288.37
2019091113251873000_34.2.288.4
2019091113251873000_34.2.288.36
2019091113251873000_34.2.288.5
2019091113251873000_34.2.288.35
2019091113251873000_34.2.288.12
2019091113251873000_34.2.288.34
2019091113251873000_34.2.288.11
2019091113251873000_34.2.288.33
2019091113251873000_34.2.288.10
2019091113251873000_34.2.288.32
2019091113251873000_34.2.288.30
(2019091113251873000_34.2.288.18) 2004; 21
(2019091113251873000_34.2.288.2) 2005; 230
2019091113251873000_34.2.288.29
2019091113251873000_34.2.288.28
(2019091113251873000_34.2.288.6) 1989; 9
2019091113251873000_34.2.288.27
2019091113251873000_34.2.288.25
2019091113251873000_34.2.288.24
2019091113251873000_34.2.288.23
References_xml – volume: 193
  start-page: 265
  year: 1951
  ident: 2019091113251873000_34.2.288.20
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(19)52451-6
– ident: 2019091113251873000_34.2.288.29
  doi: 10.1016/0092-8674(94)90212-7
– volume: 202
  start-page: 172
  year: 1995
  ident: 2019091113251873000_34.2.288.26
  publication-title: Dev Dyn
  doi: 10.1002/aja.1002020209
– ident: 2019091113251873000_34.2.288.11
  doi: 10.1681/ASN.2004100882
– ident: 2019091113251873000_34.2.288.5
  doi: 10.1073/pnas.86.2.695
– volume: 275
  start-page: 1011
  year: 1995
  ident: 2019091113251873000_34.2.288.31
  publication-title: J Pharmacol Exp Ther
– ident: 2019091113251873000_34.2.288.12
  doi: 10.1016/j.transproceed.2004.01.051
– volume: 18
  start-page: 957
  year: 2001
  ident: 2019091113251873000_34.2.288.7
  publication-title: Pharm Res (NY)
  doi: 10.1023/A:1010984110732
– ident: 2019091113251873000_34.2.288.9
  doi: 10.1146/annurev.bi.62.070193.002125
– volume: 61
  start-page: 1469
  year: 2001
  ident: 2019091113251873000_34.2.288.15
  publication-title: Cancer Res
– ident: 2019091113251873000_34.2.288.24
  doi: 10.1016/j.transproceed.2003.12.053
– ident: 2019091113251873000_34.2.288.27
  doi: 10.1046/j.1440-169X.2003.00699.x
– ident: 2019091113251873000_34.2.288.30
  doi: 10.1172/JCI118214
– ident: 2019091113251873000_34.2.288.3
  doi: 10.1042/bj3260539
– volume: 21
  start-page: 1284
  year: 2004
  ident: 2019091113251873000_34.2.288.18
  publication-title: Pharm Res (NY)
  doi: 10.1023/B:PHAM.0000033017.52484.81
– volume: 49
  start-page: 250
  year: 2001
  ident: 2019091113251873000_34.2.288.21
  publication-title: J Investig Med
  doi: 10.2310/6650.2001.33969
– ident: 2019091113251873000_34.2.288.33
  doi: 10.2165/00003088-200342020-00001
– ident: 2019091113251873000_34.2.288.39
  doi: 10.1097/00007890-200208270-00024
– ident: 2019091113251873000_34.2.288.1
  doi: 10.1007/s004670050607
– ident: 2019091113251873000_34.2.288.36
  doi: 10.1159/000047185
– ident: 2019091113251873000_34.2.288.16
  doi: 10.1016/j.transproceed.2004.01.013
– volume: 230
  start-page: 118
  year: 2005
  ident: 2019091113251873000_34.2.288.2
  publication-title: Exp Biol Med (Maywood)
  doi: 10.1177/153537020523000206
– volume: 9
  start-page: 1346
  year: 1989
  ident: 2019091113251873000_34.2.288.6
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.9.3.1346
– ident: 2019091113251873000_34.2.288.38
  doi: 10.1038/sj.jp.7210633
– ident: 2019091113251873000_34.2.288.34
  doi: 10.1046/j.1472-8206.2003.00140.x
– volume: 270
  start-page: F756
  year: 1996
  ident: 2019091113251873000_34.2.288.14
  publication-title: Am J Physiol
– ident: 2019091113251873000_34.2.288.19
  doi: 10.1006/meth.2001.1262
– ident: 2019091113251873000_34.2.288.10
  doi: 10.1124/dmd.30.3.283
– ident: 2019091113251873000_34.2.288.22
  doi: 10.1002/(SICI)1097-4695(19990605)39:3<383::AID-NEU5>3.0.CO;2-4
– ident: 2019091113251873000_34.2.288.23
  doi: 10.1111/j.1476-5381.1996.tb15775.x
– ident: 2019091113251873000_34.2.288.4
  doi: 10.1124/dmd.105.003640
– volume: 2
  start-page: 45
  year: 1998
  ident: 2019091113251873000_34.2.288.13
  publication-title: Pediatr Transplant
– ident: 2019091113251873000_34.2.288.25
  doi: 10.1007/s004670100602
– ident: 2019091113251873000_34.2.288.32
  doi: 10.1007/s004180050159
– ident: 2019091113251873000_34.2.288.35
  doi: 10.1007/s00467-003-1347-2
– ident: 2019091113251873000_34.2.288.37
  doi: 10.1016/S0009-9120(01)00235-1
– ident: 2019091113251873000_34.2.288.17
  doi: 10.1210/en.142.6.2686
– ident: 2019091113251873000_34.2.288.28
  doi: 10.1073/pnas.94.8.4028
– ident: 2019091113251873000_34.2.288.8
  doi: 10.1038/sj.bjp.0705227
SSID ssj0014439
Score 2.0201318
Snippet Cyclosporin A (CyA) toxicity is a common occurrence in pediatric organ transplant patients. We hypothesized that reduced mdr1a expression in newborn and...
SourceID proquest
crossref
pubmed
pascalfrancis
highwire
SourceType Aggregation Database
Index Database
Publisher
StartPage 288
SubjectTerms Age Factors
Animals
Animals, Newborn
ATP Binding Cassette Transporter, Subfamily B - deficiency
ATP Binding Cassette Transporter, Subfamily B - genetics
ATP Binding Cassette Transporter, Subfamily B - metabolism
ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism
ATP-Binding Cassette Sub-Family B Member 4
ATP-Binding Cassette Transporters - genetics
ATP-Binding Cassette Transporters - metabolism
Biological and medical sciences
Brain - metabolism
Cyclosporine - blood
Cyclosporine - pharmacokinetics
Female
Gene Expression Regulation
Immunosuppressive Agents - blood
Immunosuppressive Agents - pharmacokinetics
Kidney - metabolism
Liver - metabolism
Male
Medical sciences
Mice
Mice, Knockout
Pharmacology. Drug treatments
RNA, Messenger - metabolism
Sex Factors
Title BRAIN CYCLOSPORIN A LEVELS ARE DETERMINED BY ONTOGENIC REGULATION OF MDR1A EXPRESSION
URI http://dmd.aspetjournals.org/content/34/2/288.abstract
https://www.ncbi.nlm.nih.gov/pubmed/16303871
https://search.proquest.com/docview/19742385
Volume 34
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLVg2LBBvCkMgxdoWHQCedh5LMtLIxBokFoxu8jP0UidtmrTRfn6uTd24lQwErCJorh1qpwT9177-FxCXltRloKbOLKJ1pCgGB1JJlWUGAPheWqMlLhR-Nv3_HTGvpzz8yAba3eXNPKt-vXHfSX_gypcA1xxl-w_INt3ChfgHPCFIyAMx7_C-D3WdxirnZovMTvFqYvxHFVAmzEKurSXurggE40KoKfWsvnCF-1qV9f1OhHo9O8UsYthuPpxvb3AItPAlHlXTUNf9kqvXryD2_x9AeyvZr3ehVrOE-UVIW7mJgiMIWLe-EraaLPVhJafnWox6O0H0xK9xMMPtVUcVdy5hndDrZ-3vBxkvH7cdLX9fh_PUwYg6CuN9YjR5pw5J4EBuKurFl2IK3ElPgn_a73asGu6Te6kaAeIS_c_wloTY5lLkvwP9taecOt3-zdGg1nf1X4U0zlLo7BWbODdsq4oys1ZSxu9TO-Tez7toBPHoQfkllk8JMdnzrd8d0KnYRve5oQe07PgaL57RGYt0eiAaHRCHdEoEI0GolG5oz3RaCAaXVraEo0Goj0ms8-fph9OI1-PI1JZyZookUrawupcWJ3JMs2YySXPJCsls1IYziXEj3GurNJSJTovlOVMm5SXospNlj0hB4vlwjwjNBaxTIsiT0yuWGyZiAW3KlOZtcpaXozIm-751itnu1K36WrKagAFznntQBmRo-7x16vBs6kzVqc18Ao-sAdK6K9gVc7iakRedSjVMLbigplYmOV2UycV6hhKPiJPHXjhu54Hz29seUHuhtfikBw06615CfFrI49a-l0DEzOeKg
link.rule.ids 315,783,787,27937,27938
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brain+cyclosporin+A+levels+are+determined+by+ontogenic+regulation+of+mdr1a+expression&rft.jtitle=Drug+metabolism+and+disposition&rft.au=Goralski%2C+Kerry+B&rft.au=Acott%2C+Philip+D&rft.au=Fraser%2C+Albert+D&rft.au=Worth%2C+David&rft.date=2006-02-01&rft.issn=0090-9556&rft.volume=34&rft.issue=2&rft.spage=288&rft_id=info:doi/10.1124%2Fdmd.105.007427&rft_id=info%3Apmid%2F16303871&rft.externalDocID=16303871
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-9556&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-9556&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-9556&client=summon